No Prescription |
 |
 | ||
|
STEMETIL Compazine |
|
| ||
No Prescription » Prescription Drugs 15 » STEMETIL Compazine Prochlorperazine is used to treat the nausea and vomiting caused by radiation therapy cancer chemotherapy surgery and other conditions. It is also used to treat psychotic symptoms such as hallucinations and hostility. Buy STEMETIL Compazine and other Prescription Drugs 15 products online at Medstore. 583
About STEMETIL Compazine: Product Type: Prescription Drugs 15 STEMETIL ( Compazine Compro Generic Prochlorperazine ) STEMETIL (Compazine Compro Generic Prochlorperazine) Compazine Compro Generic Prochlorperazine 5mg Tabs 10 Compazine Compro Generic Prochlorperazine STEMETIL
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
